Home › Calculator › TNXP Dividend Calculator 2026
TNXP Dividend DRIP Calculator 2026
16.79% YieldHealthcareTonix Pharmaceuticals Holding Corp. · NASDAQ
Price: $11.91 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When TNXP pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your TNXP snowball 📈
$10,000 in TNXP → $11.8K in 10 years · $0.16/month
About Tonix Pharmaceuticals Holding Corp. (TNXP) — Dividend Analysis 2026
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Compare TNXP with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full TNXP DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open TNXP position with:
🌍 TNXP Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold TNXP.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 16.79% | 13.99% | $1,679 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 14.27% | 11.47% | $1,427 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 13.43% | 10.63% | $1,343 / yr |
| 🇬🇧 UK ISA | 0% | 16.79% | 13.99% | $1,679 / yr |
| 🇬🇧 UK Taxable | 8.75% | 15.32% | 12.52% | $1,532 / yr |
| 🇨🇦 TFSA | 0% | 16.79% | 13.99% | $1,679 / yr |
| 🇨🇦 CA Taxable | 25% | 12.59% | 9.79% | $1,259 / yr |
| 🇦🇺 Super (pension) | 15% | 14.27% | 11.47% | $1,427 / yr |
| 🇦🇺 AU Taxable | 30% | 11.75% | 8.95% | $1,175 / yr |
| 🇩🇪 DE Taxable | 26.375% | 12.36% | 9.56% | $1,236 / yr |
| 🇫🇷 FR Taxable | 30% | 11.75% | 8.95% | $1,175 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 TNXP Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 TNXP Dividend Payment Schedule
TNXP pays quarterly — 4 times per year. Next ex-div: TBD.
📊 TNXP vs Healthcare Benchmarks
How TNXP compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for TNXP sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ TNXP Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Other | 2025-09-09 | 500 | $16.51 | $8.3K | ||
| Other | 2026-02-25 | 6,500 | $8.05 | $52.3K | ||
| Other | 2026-05-13 | 12,480 | $20.18 | $251.8K | ||
| Other | 2027-02-24 | 40,000 | $14.29 | $571.6K | ||
| Buy | 2026-08-27 | 2,000 | $13.79 | $27.6K | ||
| Buy | 2026-08-20 | 1,000 | $12.60 | $12.6K | ||
| J-Other | 2026-06-30 | 1,453 | $10.91 | $15.9K | ||
| Buy | 2026-06-12 | 1,415 | $10.55 | $14.9K | ||
| Buy | 2026-06-08 | 5,000 | $11.65 | $58.3K | ||
| Buy | 2026-06-09 | 5,000 | $11.79 | $59.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Insiders are net buyers — historically a positive signal for dividend sustainability. Last purchase: 2026-08-27
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the TNXP dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Tonix Pharmaceuticals Holding Corp. (TNXP) is currently trading at $11.91, 100% below its 52-week high. The current dividend yield is 16.79% based on an annual payout of $2.00 per share.
TNXP (Tonix Pharmaceuticals Holding Corp.) — 16.79% Dividend Yield Analysis
Tonix Pharmaceuticals Holding Corp. (TNXP) is a healthcare stock currently trading at $11.91 with a dividend yield of 16.79%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, TNXP has grown its dividend at a compound annual rate of 50.0%.
- Above-average yield (16.79%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.